Fractyl Health (GUTS) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Brian Luque - Head - IR & Corporate DevelopmentHarith Rajagopalan - Co-Founder, CEO & DirectorLisa Davidson - CFO & TreasurerChi Fong - VP - Equity ResearchAvraham Novick - Biotech Equity Research AssociateMichael Difiore - Managing DirectorWhitney Ijem - Managing Director Operator Good afternoon, and welcome to Fractal Health's First Quarter twenty twenty five Financial Results and Business Updates Call. As a reminder ...

Fractyl Health (GUTS) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Fractal Health's First Quarter twenty twenty five Financial Results and Business Updates Call. As a reminder, this conference call is being recorded. At this time, all participants are in listen only mode. There will be a question and answer session following management's prepared remarks. I'll now turn the call over to Brian Lucay, Head of Investor Relations and Corporate Development at Fractal. Bri ...

May 12, 2025 01:56 AM GMT Eli Lilly & Co. | North America Tidbits from Zepbound vs. Wegovy SURMOUNT-5 obesity publication Investigators published SURMOUNT-5 Ph3 obesity data from a head-to-head trial of LLY's Zepbound (Tirzepatide MTD 10/15mg) vs. Novo's Wegovy (Semaglutide MTD 1.7/2.4mg) in the New England Journal of Medicine (LINK). Recall top-line data from the trial were reported in Dec 2024, see our prior note HERE. In the Zepbound group, 89.3% of the participants received at least one 15mg dose, and i ...

Core Insights - Eli Lilly's Zepbound (tirzepatide) demonstrated superior efficacy in weight loss compared to Wegovy (semaglutide) in the SURMOUNT-5 trial, achieving an average weight loss of 20.2% versus 13.7% at 72 weeks [1][2][3] Group 1: Trial Results - Zepbound participants lost an average of 50.3 lbs (22.8 kg), while Wegovy participants lost an average of 33.1 lbs (15.0 kg), indicating a 47% greater relative weight loss with Zepbound [2] - In key secondary endpoints, 64.6% of Zepbound participants achieved at least 15% weight loss compared to 40.1% for Wegovy [2][5] - Zepbound also showed a greater average waist circumference reduction of 7.2 inches (18.4 cm) compared to 5.1 inches (13.0 cm) for Wegovy [2][5] Group 2: Safety and Tolerability - The safety profile of Zepbound was consistent with previous trials, with gastrointestinal-related adverse events being the most common and generally mild to moderate [5] - 6.1% of Zepbound participants discontinued treatment due to adverse events, compared to 8.0% for Wegovy [5] Group 3: Product Information - Tirzepatide is marketed as Zepbound in the U.S. for adults with obesity or overweight with weight-related medical problems, and as Mounjaro for type 2 diabetes [6][10] - Zepbound is FDA-approved for adults with moderate-to-severe obstructive sleep apnea and obesity [10]

Skye Bioscience (SKYE) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by. My name is JL, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sky BioScience First Quarter Fiscal twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Bernie He ...

Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity modelIn vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonistsExpanded preclinical study data to be presented at ADA in June 2025Top-line data readout from CBeyond™ P ...

Skye Bioscience (SKYE) 2025 Conference May 08, 2025 11:00 AM ET Speaker0 two of the Citizens Life Science Conference. My name is John Walden, senior analyst here. We're pleased to have Sky Bioscience and Puneet Dillon, CEO joining us to tell us a little bit about the story. Sky, we initiated coverage on just a little while ago, but, this is a name that I think is underappreciated in the obesity space going after, you know, a relatively novel well, not novel mechanism, but way less crowded space with some di ...

Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants David Connolly - Executive Director, Investor Relations and Corporate CommunicationsDavid Meeker - Chairman, President & CEOJennifer Lee - Executive Vice President, Head of North AmericaYann Mazabraud - Executive VP & Head of InternationalHunter Smith - Chief Financial OfficerJon Wolleben - Managing DirectorTazeen Ahmad - MD - US Equity ResearchSeamus Fernandez - Senior Managing DirectorWhitney Ijem - Managing ...

Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Please be advised that today's conference is being recorded. After the speakers' presentation, there will be a question and answer session. I would now like to hand the conference over to your speaker today, David Connolly, Investo ...

Rhythm Pharmaceuticals First Quarter 2025 Financial Results and Business Update May 7, 2025 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. On Today's Call ® 2 • David Connolly, Executive Director of Investor Relations and Corporate Communications • David Meeker, MD, Chair, President and Chief Executive Officer • Jennifer Lee, Executive Vice President, Head of North America • Yann Mazabraud, Executive Vice President, Head of International • Hunter Smith, Chief Financial Officer Forward-looking Statem ...